<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02141516</url>
  </required_header>
  <id_info>
    <org_study_id>V72_62</org_study_id>
    <secondary_id>2013-002454-78</secondary_id>
    <nct_id>NCT02141516</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.</brief_title>
  <official_title>A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Immunocompromised Patients From 2 to 17 Years of Age Who Are at Increased Risk of Meningococcal Disease Because of Complement Deficiency or Asplenia Compared to Matched Healthy Controls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered
      to subjects from 2 to 17 years of age with increased risk of meningococcal disease because
      either of primary or secondary complement deficiencies or of asplenia or splenic dysfunction.
      A group of healthy age-matched subjects will be enrolled to serve as a descriptive control
      for immunogenicity and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Titers ≥ 5 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.</measure>
    <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine)</time_frame>
    <description>Immunogenicity was assessed in terms of percentage of subjects with hSBA titers ≥ 5 against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+Outer Membrane Vesicle (OMV) NZ, administered on Day 1 and Day 61.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 8 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.</measure>
    <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
    <description>Immunogenicity was assessed in terms of percentage of subjects with hSBA titers ≥ 8 against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratios (GMRs) Against N. Meningitidis Serogroup B Strains Following a 2-dose Vaccination Schedule.</measure>
    <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
    <description>Immunogenicity was assessed in terms of GMRs against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean hSBA Titers (GMTs) Against N. Meningitidis Serogroup B Strains Following a 2-dose Vaccination Schedule.</measure>
    <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
    <description>Immunogenicity was assessed in terms of GMTs against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects With Four-fold Increases in hSBA Titers Against the Serogroup B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.</measure>
    <time_frame>Day 91 (one month after the second dose of the study vaccine).</time_frame>
    <description>Antibody responses were assessed in terms of percentage of subjects achieving 4-fold increase in ELISA concentrations against vaccine antigen 287-953 on Day 91 over baseline (Day 1), following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Antibodies Against Vaccine Antigen 287-953 Following a 2-dose Vaccination Schedule.</measure>
    <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
    <description>Immune responses were measured as Enzyme-linked Immunosorbent Assay (ELISA) GMCs of antibodies against vaccine antigen 287-953 following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ELISA GMRs of Antibodies Against Vaccine Antigen 287-953 Following a 2-dose Vaccination Schedule.</measure>
    <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
    <description>Immune responses were measured as ELISA GMRs of antibodies against vaccine antigen 287-953 following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Four-fold Increases in ELISA Concentrations Against the Vaccine Antigen 287-953.</measure>
    <time_frame>Day 91 (one month after the second dose of the study vaccine).</time_frame>
    <description>Antibody responses were assessed in terms of percentage of subjects achieving 4-fold increase in ELISA concentrations against vaccine antigen 287-953 on Day 91 over baseline (Day 1), following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Subjects With Unsolicited Adverse Events (AEs).</measure>
    <time_frame>At Day1 through Day 7 after any vaccination and throughout the study period (Day 1 to Day 91)</time_frame>
    <description>Safety was assessed as the number of subjects who reported unsolicited AEs collected from Day1 through Day 7 after any vaccination; serious adverse events (SAEs), AEs leading to withdrawal and medically attended AEs were collected throughout the study period (Day1-Day 91).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic AEs.</measure>
    <time_frame>From Day 1 until Day 7 after any vaccination.</time_frame>
    <description>Reactogenicity was presented in terms of percentages of subjects reporting solicited local and systemic AEs and other indicators.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complement deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>asplenia/splenic dysfunction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>age-matched healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV</intervention_name>
    <description>2 doses of vaccine 2 months apart</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV</intervention_name>
    <description>2 doses of vaccine 2 months apart</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV</intervention_name>
    <description>2 doses of vaccine 2 months apart</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criterion applicable to All Groups

          -  Subjects aged 2 to 17 years (inclusive) at enrollment

          -  weighing at least 13 Kg at the time of enrollment

        Inclusion criterion applicable to Group A - Subjects at risk of meningococcal disease
        because of primary or secondary complement deficiencies

        Inclusion criterion applicable to Group B

        - Subjects at risk of meningococcal disease because of functional or anatomic asplenia

        Inclusion criterion applicable to Group C - healthy subjects

        Exclusion Criteria:

        Exclusion criteria applicable to All Groups (A, B and C)

          -  History of any previous immunization with a meningococcal B vaccine

          -  History of severe allergic reaction after previous vaccinations, or hypersensitivity
             to any component of the vaccine

          -  Known HIV infection

          -  History of any progressive or severe neurologic disorder or seizure disorder

          -  Contraindication to intramuscular injection or blood drawn

          -  Females who are pregnant, planning a pregnancy or nursing (breastfeeding)

          -  Females of childbearing potential who have not used or do not plan to use acceptable
             birth control measures

          -  History or any illness/condition that, in the opinion of the investigator, might
             interfere with the results of the study or pose additional risk to the subjects

        Exclusion criterion applicable to Groups A and B

        - Previous known or suspected disease caused by N. meningitidis in the last year.

        Exclusion criteria applicable to Group C

          -  Previous known or suspected disease caused by N. meningitidis

          -  Known or suspected impairment/alteration of the immune system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>12, Novartis Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>11, Novartis Investigational Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10, Novartis Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>14, Novartis Investigational Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>13, Novartis Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>31, Novartis Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>33, Novartis Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>30, Novartis Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-345</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>42, Novartis Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>41, Novartis Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>43, Novartis Investigational Site</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>21, Novartis Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>22, Novartis Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>23, Novartis Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>20, Novartis Investigational Site</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>24, Novartis Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>53, Novartis Investigational Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>52, Novartis Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>50, Novartis Investigational Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>51, Novartis Investigational Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2014</study_first_posted>
  <results_first_submitted>March 3, 2016</results_first_submitted>
  <results_first_submitted_qc>December 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2017</results_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis</keyword>
  <keyword>vaccination</keyword>
  <keyword>complement deficiency</keyword>
  <keyword>asplenia</keyword>
  <keyword>splenic dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Complement System Proteins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 4 centers in Italy, 3 centers in Poland, 3 centers in the Russian Federation, 4 centers in Spain and 4 centers in the United Kingdom.</recruitment_details>
      <pre_assignment_details>All the enrolled subjects were included in the trial. One subject did not complete the study because he/she did not meet criteria for re-vaccination; two subjects met enrollment delay criteria since they required regular blood transfusions and they were unable to commit to visit windows (screen failure).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CompDef</title>
          <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
        <group group_id="P2">
          <title>Asplenia</title>
          <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
        <group group_id="P3">
          <title>Healthy</title>
          <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CompDef</title>
          <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
        <group group_id="B2">
          <title>Asplenia</title>
          <description>Subjects aged ≥ 2 to ≤17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
        <group group_id="B3">
          <title>Healthy</title>
          <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="112"/>
            <count group_id="B3" value="87"/>
            <count group_id="B4" value="239"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="4.35"/>
                    <measurement group_id="B2" value="11.1" spread="3.7"/>
                    <measurement group_id="B3" value="10.2" spread="4.14"/>
                    <measurement group_id="B4" value="10.3" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Titers ≥ 5 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.</title>
        <description>Immunogenicity was assessed in terms of percentage of subjects with hSBA titers ≥ 5 against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+Outer Membrane Vesicle (OMV) NZ, administered on Day 1 and Day 61.</description>
        <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine)</time_frame>
        <population>Analysis was done on Full Analysis Set (all subjects in the enrolled set who: received a study vaccination and provided an evaluable serum sample at 1 month after the second dose of rMenB+OMV NZ, with assay result available for at least one of the serogroup B indicator strains or M10713 strain or ELISA).</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Titers ≥ 5 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.</title>
          <description>Immunogenicity was assessed in terms of percentage of subjects with hSBA titers ≥ 5 against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+Outer Membrane Vesicle (OMV) NZ, administered on Day 1 and Day 61.</description>
          <population>Analysis was done on Full Analysis Set (all subjects in the enrolled set who: received a study vaccination and provided an evaluable serum sample at 1 month after the second dose of rMenB+OMV NZ, with assay result available for at least one of the serogroup B indicator strains or M10713 strain or ELISA).</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 - Day 1 (N=37,103,140,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9.5"/>
                    <measurement group_id="O2" value="12" lower_limit="6.2" upper_limit="19.5"/>
                    <measurement group_id="O3" value="9" lower_limit="4.5" upper_limit="14.5"/>
                    <measurement group_id="O4" value="6" lower_limit="2" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 - Day 91 (N=38,106,144,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="82.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="100" lower_limit="96.6" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="95.1" upper_limit="99.83"/>
                    <measurement group_id="O4" value="99" lower_limit="93.5" upper_limit="99.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - Day 1 (N=39,104,143,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="7" lower_limit="2.7" upper_limit="13.4"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="9.8"/>
                    <measurement group_id="O4" value="6" lower_limit="2" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - Day 91 (N=39,104,143,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="72.6" upper_limit="95.7"/>
                    <measurement group_id="O2" value="97" lower_limit="91.8" upper_limit="99.4"/>
                    <measurement group_id="O3" value="94" lower_limit="89.3" upper_limit="97.6"/>
                    <measurement group_id="O4" value="98" lower_limit="91.8" upper_limit="99.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 - Day 1 (N=36,102,138,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="38.1" upper_limit="72.1"/>
                    <measurement group_id="O2" value="79" lower_limit="70.3" upper_limit="86.8"/>
                    <measurement group_id="O3" value="73" lower_limit="65" upper_limit="80.4"/>
                    <measurement group_id="O4" value="78" lower_limit="67.5" upper_limit="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 - Day 91 (N=37,103,140,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="55.9" upper_limit="86.2"/>
                    <measurement group_id="O2" value="94" lower_limit="87.8" upper_limit="97.8"/>
                    <measurement group_id="O3" value="89" lower_limit="82.1" upper_limit="93.3"/>
                    <measurement group_id="O4" value="99" lower_limit="93.5" upper_limit="99.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 - Day 1 (N=36,105,141,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9.7"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="9.5"/>
                    <measurement group_id="O3" value="3" lower_limit="0.8" upper_limit="7.1"/>
                    <measurement group_id="O4" value="2" lower_limit="0.29" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 - Day 91 (N=38,106,144,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="51.3" upper_limit="82.5"/>
                    <measurement group_id="O2" value="86" lower_limit="77.7" upper_limit="91.9"/>
                    <measurement group_id="O3" value="81" lower_limit="73.9" upper_limit="87.3"/>
                    <measurement group_id="O4" value="83" lower_limit="73.6" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 8 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.</title>
        <description>Immunogenicity was assessed in terms of percentage of subjects with hSBA titers ≥ 8 against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
        <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
        <population>Analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 8 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.</title>
          <description>Immunogenicity was assessed in terms of percentage of subjects with hSBA titers ≥ 8 against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
          <population>Analysis was done on Full Analysis Set</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 - Day 1 (N=37,103,140,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9.5"/>
                    <measurement group_id="O2" value="11" lower_limit="5.5" upper_limit="18.3"/>
                    <measurement group_id="O3" value="8" lower_limit="4" upper_limit="13.6"/>
                    <measurement group_id="O4" value="5" lower_limit="1.3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 - Day 91 (N=38,106,144,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="78.6" upper_limit="98.3"/>
                    <measurement group_id="O2" value="100" lower_limit="96.6" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="94" upper_limit="99.57"/>
                    <measurement group_id="O4" value="99" lower_limit="93.5" upper_limit="99.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - Day 1 (N=39,104,143,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="2" lower_limit="0.23" upper_limit="6.8"/>
                    <measurement group_id="O3" value="1" lower_limit="0.17" upper_limit="5"/>
                    <measurement group_id="O4" value="2" lower_limit="0.29" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - Day 91 (N=39,104,143,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="72.6" upper_limit="95.7"/>
                    <measurement group_id="O2" value="95" lower_limit="89.1" upper_limit="98.4"/>
                    <measurement group_id="O3" value="93" lower_limit="87.5" upper_limit="96.6"/>
                    <measurement group_id="O4" value="98" lower_limit="91.8" upper_limit="99.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 - Day 1 (N=36,102,138,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="30.4" upper_limit="64.5"/>
                    <measurement group_id="O2" value="68" lower_limit="57.7" upper_limit="76.6"/>
                    <measurement group_id="O3" value="62" lower_limit="53.7" upper_limit="70.4"/>
                    <measurement group_id="O4" value="68" lower_limit="57.1" upper_limit="78.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 - Day 91 (N=37,103,140,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="53" upper_limit="84.1"/>
                    <measurement group_id="O2" value="94" lower_limit="87.8" upper_limit="97.8"/>
                    <measurement group_id="O3" value="88" lower_limit="81.3" upper_limit="92.8"/>
                    <measurement group_id="O4" value="98" lower_limit="91.6" upper_limit="99.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 - Day 1 (N=36,105,141,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9.7"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="9.5"/>
                    <measurement group_id="O3" value="3" lower_limit="0.8" upper_limit="7.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 - Day 91 (N=38,106,144,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="46" upper_limit="78.2"/>
                    <measurement group_id="O2" value="79" lower_limit="70.3" upper_limit="86.5"/>
                    <measurement group_id="O3" value="75" lower_limit="67.1" upper_limit="81.8"/>
                    <measurement group_id="O4" value="73" lower_limit="61.8" upper_limit="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratios (GMRs) Against N. Meningitidis Serogroup B Strains Following a 2-dose Vaccination Schedule.</title>
        <description>Immunogenicity was assessed in terms of GMRs against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
        <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
        <population>Analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratios (GMRs) Against N. Meningitidis Serogroup B Strains Following a 2-dose Vaccination Schedule.</title>
          <description>Immunogenicity was assessed in terms of GMRs against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
          <population>Analysis was done on Full Analysis Set</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 - Day 91/Day 1 (N=37,103,140,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299" lower_limit="170" upper_limit="525"/>
                    <measurement group_id="O2" value="207" lower_limit="149" upper_limit="288"/>
                    <measurement group_id="O3" value="228" lower_limit="173" upper_limit="302"/>
                    <measurement group_id="O4" value="245" lower_limit="187" upper_limit="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - Day 91/Day 1 (N=39,104,143,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="27" upper_limit="73"/>
                    <measurement group_id="O2" value="56" lower_limit="41" upper_limit="75"/>
                    <measurement group_id="O3" value="52" lower_limit="41" upper_limit="67"/>
                    <measurement group_id="O4" value="66" lower_limit="52" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 - Day 91/Day 1 (N=36,102,138,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.37" upper_limit="3.71"/>
                    <measurement group_id="O2" value="2.95" lower_limit="2.21" upper_limit="3.95"/>
                    <measurement group_id="O3" value="2.75" lower_limit="2.15" upper_limit="3.51"/>
                    <measurement group_id="O4" value="2.71" lower_limit="2.02" upper_limit="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 - Day 91/Day 1 (N=36,105,141,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58" lower_limit="4.9" upper_limit="15"/>
                    <measurement group_id="O2" value="16" lower_limit="12" upper_limit="22"/>
                    <measurement group_id="O3" value="14" lower_limit="10" upper_limit="18"/>
                    <measurement group_id="O4" value="13" lower_limit="10" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean hSBA Titers (GMTs) Against N. Meningitidis Serogroup B Strains Following a 2-dose Vaccination Schedule.</title>
        <description>Immunogenicity was assessed in terms of GMTs against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
        <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
        <population>Analysis was done on Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers (GMTs) Against N. Meningitidis Serogroup B Strains Following a 2-dose Vaccination Schedule.</title>
          <description>Immunogenicity was assessed in terms of GMTs against N. meningitidis serogroup B indicator strains (H44/76, 5/99, and NZ98/254) and M10713 strain following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
          <population>Analysis was done on Full Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 - Day 1 (N=37,103,140,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.61" upper_limit="1.26"/>
                    <measurement group_id="O2" value="1.43" lower_limit="1.16" upper_limit="1.78"/>
                    <measurement group_id="O3" value="1.26" lower_limit="1.05" upper_limit="1.51"/>
                    <measurement group_id="O4" value="1.24" lower_limit="1.02" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 - Day 91 (N=38,106,144,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263" lower_limit="166" upper_limit="415"/>
                    <measurement group_id="O2" value="300" lower_limit="230" upper_limit="392"/>
                    <measurement group_id="O3" value="290" lower_limit="231" upper_limit="362"/>
                    <measurement group_id="O4" value="307" lower_limit="250" upper_limit="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - Day 1 (N=39,104,143,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.87" upper_limit="1.33"/>
                    <measurement group_id="O2" value="1.17" lower_limit="1.03" upper_limit="1.32"/>
                    <measurement group_id="O3" value="1.14" lower_limit="1.03" upper_limit="1.26"/>
                    <measurement group_id="O4" value="1.15" lower_limit="1.03" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - Day 91 (N=39,104,143,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="29" upper_limit="79"/>
                    <measurement group_id="O2" value="65" lower_limit="48" upper_limit="88"/>
                    <measurement group_id="O3" value="60" lower_limit="46" upper_limit="77"/>
                    <measurement group_id="O4" value="76" lower_limit="61" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 - Day 1 (N=36,102,138,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57" lower_limit="4.43" upper_limit="17"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="22"/>
                    <measurement group_id="O3" value="13" lower_limit="9.44" upper_limit="18"/>
                    <measurement group_id="O4" value="16" lower_limit="11" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 - Day 91 (N=37,103,140,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="11" upper_limit="34"/>
                    <measurement group_id="O2" value="45" lower_limit="33" upper_limit="62"/>
                    <measurement group_id="O3" value="36" lower_limit="28" upper_limit="47"/>
                    <measurement group_id="O4" value="42" lower_limit="34" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 - Day 1 (N=36,105,141,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.78" upper_limit="1.16"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.98" upper_limit="1.24"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.96" upper_limit="1.17"/>
                    <measurement group_id="O4" value="1.05" lower_limit="0.98" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 - Day 91 (N=38,106,144,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.46" lower_limit="4.85" upper_limit="15"/>
                    <measurement group_id="O2" value="18" lower_limit="13" upper_limit="24"/>
                    <measurement group_id="O3" value="14" lower_limit="11" upper_limit="19"/>
                    <measurement group_id="O4" value="14" lower_limit="10" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Four-fold Increases in hSBA Titers Against the Serogroup B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.</title>
        <description>Antibody responses were assessed in terms of percentage of subjects achieving 4-fold increase in ELISA concentrations against vaccine antigen 287-953 on Day 91 over baseline (Day 1), following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
        <time_frame>Day 91 (one month after the second dose of the study vaccine).</time_frame>
        <population>Analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Four-fold Increases in hSBA Titers Against the Serogroup B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain.</title>
          <description>Antibody responses were assessed in terms of percentage of subjects achieving 4-fold increase in ELISA concentrations against vaccine antigen 287-953 on Day 91 over baseline (Day 1), following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
          <population>Analysis was done on Full Analysis Set</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5/99 - Day 91 (N=37,103,140,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="78.1" upper_limit="98.3"/>
                    <measurement group_id="O2" value="100" lower_limit="96.5" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="93.9" upper_limit="99.56"/>
                    <measurement group_id="O4" value="98" lower_limit="91.5" upper_limit="99.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 - Day 91 (N=39,104,143,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="72.6" upper_limit="95.7"/>
                    <measurement group_id="O2" value="94" lower_limit="87.9" upper_limit="97.9"/>
                    <measurement group_id="O3" value="92" lower_limit="86.7" upper_limit="96.1"/>
                    <measurement group_id="O4" value="98" lower_limit="91.7" upper_limit="99.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 - Day 91 (N=36,102,138,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="12.1" upper_limit="42.2"/>
                    <measurement group_id="O2" value="33" lower_limit="24.3" upper_limit="43.4"/>
                    <measurement group_id="O3" value="31" lower_limit="23.6" upper_limit="39.6"/>
                    <measurement group_id="O4" value="33" lower_limit="22.9" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 - Day 91 (N=36,105,141,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="43.5" upper_limit="76.9"/>
                    <measurement group_id="O2" value="80" lower_limit="71.1" upper_limit="87.2"/>
                    <measurement group_id="O3" value="75" lower_limit="67.2" upper_limit="82.1"/>
                    <measurement group_id="O4" value="73" lower_limit="62.7" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations (GMCs) of Antibodies Against Vaccine Antigen 287-953 Following a 2-dose Vaccination Schedule.</title>
        <description>Immune responses were measured as Enzyme-linked Immunosorbent Assay (ELISA) GMCs of antibodies against vaccine antigen 287-953 following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
        <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
        <population>Analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) of Antibodies Against Vaccine Antigen 287-953 Following a 2-dose Vaccination Schedule.</title>
          <description>Immune responses were measured as Enzyme-linked Immunosorbent Assay (ELISA) GMCs of antibodies against vaccine antigen 287-953 following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
          <population>Analysis was done on Full Analysis Set</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>287-953 - Day 1 (N=39,106,145,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="25" upper_limit="43"/>
                    <measurement group_id="O2" value="25" lower_limit="21" upper_limit="29"/>
                    <measurement group_id="O3" value="27" lower_limit="23" upper_limit="31"/>
                    <measurement group_id="O4" value="27" lower_limit="23" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>287-953 - Day 91 (N=40,106,146,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2039" lower_limit="1436" upper_limit="2894"/>
                    <measurement group_id="O2" value="3418" lower_limit="2780" upper_limit="4202"/>
                    <measurement group_id="O3" value="2973" lower_limit="2492" upper_limit="3546"/>
                    <measurement group_id="O4" value="2957" lower_limit="2450" upper_limit="3570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ELISA GMRs of Antibodies Against Vaccine Antigen 287-953 Following a 2-dose Vaccination Schedule.</title>
        <description>Immune responses were measured as ELISA GMRs of antibodies against vaccine antigen 287-953 following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
        <time_frame>Day 1 and Day 91 (one month after the second dose of the study vaccine).</time_frame>
        <population>Analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMRs of Antibodies Against Vaccine Antigen 287-953 Following a 2-dose Vaccination Schedule.</title>
          <description>Immune responses were measured as ELISA GMRs of antibodies against vaccine antigen 287-953 following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
          <population>Analysis was done on Full Analysis Set</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="40" upper_limit="97"/>
                    <measurement group_id="O2" value="138" lower_limit="107" upper_limit="178"/>
                    <measurement group_id="O3" value="112" lower_limit="90" upper_limit="193"/>
                    <measurement group_id="O4" value="111" lower_limit="88" upper_limit="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Four-fold Increases in ELISA Concentrations Against the Vaccine Antigen 287-953.</title>
        <description>Antibody responses were assessed in terms of percentage of subjects achieving 4-fold increase in ELISA concentrations against vaccine antigen 287-953 on Day 91 over baseline (Day 1), following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
        <time_frame>Day 91 (one month after the second dose of the study vaccine).</time_frame>
        <population>Analysis was done on Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Four-fold Increases in ELISA Concentrations Against the Vaccine Antigen 287-953.</title>
          <description>Antibody responses were assessed in terms of percentage of subjects achieving 4-fold increase in ELISA concentrations against vaccine antigen 287-953 on Day 91 over baseline (Day 1), following 2 doses of rMenB+OMV NZ, administered on Day 1 and Day 61.</description>
          <population>Analysis was done on Full Analysis Set</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="86.5" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98" lower_limit="93.4" upper_limit="99.77"/>
                    <measurement group_id="O3" value="98" lower_limit="94.1" upper_limit="99.57"/>
                    <measurement group_id="O4" value="98" lower_limit="91.7" upper_limit="99.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic AEs.</title>
        <description>Reactogenicity was presented in terms of percentages of subjects reporting solicited local and systemic AEs and other indicators.</description>
        <time_frame>From Day 1 until Day 7 after any vaccination.</time_frame>
        <population>Analysis was done on Solicited Safety Set (all subjects in the exposed set with any solicited AE data).</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Total of subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic AEs.</title>
          <description>Reactogenicity was presented in terms of percentages of subjects reporting solicited local and systemic AEs and other indicators.</description>
          <population>Analysis was done on Solicited Safety Set (all subjects in the exposed set with any solicited AE data).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Local (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (&lt;6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits (&lt;6 years;N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C) (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention Pain/Fever (&lt;6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treat. P/F (&lt; 6 years; N=12,9,21,13,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="122"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (≥ 6 years; N=28,100,128,73,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38°C) (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prev. Pain/Fever (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treat. Pain/Fever (≥ 6 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number Of Subjects With Unsolicited Adverse Events (AEs).</title>
        <description>Safety was assessed as the number of subjects who reported unsolicited AEs collected from Day1 through Day 7 after any vaccination; serious adverse events (SAEs), AEs leading to withdrawal and medically attended AEs were collected throughout the study period (Day1-Day 91).</description>
        <time_frame>At Day1 through Day 7 after any vaccination and throughout the study period (Day 1 to Day 91)</time_frame>
        <population>Analysis was done on the Unsolicited Safety Set (all subjects in the exposed set with postvaccination unsolicited AE records).</population>
        <group_list>
          <group group_id="O1">
            <title>CompDef</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O3">
            <title>CompDef + Asplenia</title>
            <description>Subjects aged ≥ 2 to ≤ 17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
          <group group_id="O4">
            <title>Healthy</title>
            <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Subjects With Unsolicited Adverse Events (AEs).</title>
          <description>Safety was assessed as the number of subjects who reported unsolicited AEs collected from Day1 through Day 7 after any vaccination; serious adverse events (SAEs), AEs leading to withdrawal and medically attended AEs were collected throughout the study period (Day1-Day 91).</description>
          <population>Analysis was done on the Unsolicited Safety Set (all subjects in the exposed set with postvaccination unsolicited AE records).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least Possibly Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically Attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire study period (Day 1 to Day 91)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CompDef</title>
          <description>Subjects aged ≥ 2 to ≤17 years with complement deficiencies received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
        <group group_id="E2">
          <title>Asplenia</title>
          <description>Subjects aged ≥ 2 to ≤ 17 years with Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
        <group group_id="E3">
          <title>CompDef + Asplenia</title>
          <description>Subjects aged ≥ 2 to ≤17 years with either complement deficiencies or Asplenia received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
        <group group_id="E4">
          <title>Healthy</title>
          <description>Healthy subjects aged ≥ 2 to ≤ 17 years received 2 doses of rMenB+OMV NZ administered 2 months apart.</description>
        </group>
        <group group_id="E5">
          <title>Total</title>
          <description>Total number of Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS SALMONELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="232" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CRYING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="112" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="75" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="223" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>INJECTION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="74" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis’ agreement with its investigators may vary.
However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

